Royalty Pharma plc Interest Expense
Royalty Pharma plc (RPRX) reported Interest Expense of $44.23 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-09.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2024-05-09
- Royalty Pharma plc interest expense for the quarter ending 2024-03-31 was $44.23M, a 5.79% decline year-over-year.
- Royalty Pharma plc interest expense for the quarter ending 2023-12-31 was $47.26M, a 0.64% increase year-over-year.
- Royalty Pharma plc interest expense for the quarter ending 2023-09-30 was $46.03M, a 2.01% decline year-over-year.
- Royalty Pharma plc interest expense for the quarter ending 2023-06-30 was $46.95M, a 0.04% decline year-over-year.
- Royalty Pharma plc interest expense for fiscal 2023 was $187.19M, a 0.41% decline from fiscal 2022.
- Royalty Pharma plc interest expense for fiscal 2022 was $187.96M, a 13.13% increase from fiscal 2021.
- Royalty Pharma plc interest expense for fiscal 2021 was $166.14M, a 5.78% increase from fiscal 2020.
- Royalty Pharma plc interest expense for fiscal 2020 was $157.06M, a 41.52% decline from fiscal 2019.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $44.23M 10-Q · filed 2024-05-09 | $91.49M derived: sum of 2 quarters · filed 2024-05-09 | $137.52M derived: sum of 3 quarters · filed 2024-05-09 | $184.47M derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | $47.26M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $93.29M derived: sum of 2 quarters · filed 2024-02-15 | $140.24M derived: sum of 3 quarters · filed 2024-02-15 | $187.19M 10-K · filed 2024-02-15 |
| 2023-09-30 | $46.03M 10-Q · filed 2023-11-08 | $92.98M derived: sum of 2 quarters · filed 2023-11-08 | $139.93M 10-Q · filed 2023-11-08 | $186.89M derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-06-30 | $46.95M 10-Q · filed 2023-08-08 | $93.90M 10-Q · filed 2023-08-08 | $140.85M derived: sum of 3 quarters · filed 2024-05-09 | $187.83M derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-03-31 | $46.95M 10-Q · filed 2024-05-09 | $93.91M derived: sum of 2 quarters · filed 2024-05-09 | $140.88M derived: sum of 3 quarters · filed 2024-05-09 | $187.85M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $46.95M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $93.93M derived: sum of 2 quarters · filed 2024-02-15 | $140.90M derived: sum of 3 quarters · filed 2024-02-15 | $187.96M 10-K · filed 2024-02-15 |
| 2022-09-30 | $46.98M 10-Q · filed 2023-11-08 | $93.94M derived: sum of 2 quarters · filed 2023-11-08 | $141.01M 10-Q · filed 2023-11-08 | $187.98M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $46.97M 10-Q · filed 2023-08-08 | $94.03M 10-Q · filed 2023-08-08 | $141.00M derived: sum of 3 quarters · filed 2024-02-15 | $185.33M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $47.06M 10-Q · filed 2023-05-09 | $94.04M derived: sum of 2 quarters · filed 2024-02-15 | $138.36M derived: sum of 3 quarters · filed 2024-02-15 | $175.79M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $46.97M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $91.30M derived: sum of 2 quarters · filed 2024-02-15 | $128.73M derived: sum of 3 quarters · filed 2024-02-15 | $166.14M 10-K · filed 2024-02-15 |
| 2021-09-30 | $44.33M 10-Q · filed 2022-11-08 | $81.75M derived: sum of 2 quarters · filed 2022-11-08 | $119.17M 10-Q · filed 2022-11-08 | $157.01M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | $37.43M 10-Q · filed 2022-08-04 | $74.84M 10-Q · filed 2022-08-04 | $112.68M derived: sum of 3 quarters · filed 2023-02-15 | $144.13M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | $37.41M 10-Q · filed 2022-05-05 | $75.26M derived: sum of 2 quarters · filed 2023-02-15 | $106.70M derived: sum of 3 quarters · filed 2023-02-15 | $140.89M derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | $37.84M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $69.29M derived: sum of 2 quarters · filed 2023-02-15 | $103.47M derived: sum of 3 quarters · filed 2023-02-15 | $157.06M 10-K · filed 2023-02-15 |
| 2020-09-30 | $31.44M 10-Q · filed 2021-11-10 | $65.63M derived: sum of 2 quarters · filed 2021-11-10 | $119.22M 10-Q · filed 2021-11-10 | $182.56M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $34.19M 10-Q · filed 2021-08-11 | $87.77M 10-Q · filed 2021-08-11 | $151.12M derived: sum of 3 quarters · filed 2022-02-15 | $219.91M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $53.58M 10-Q · filed 2021-05-11 | $116.93M derived: sum of 2 quarters · filed 2022-02-15 | $185.72M derived: sum of 3 quarters · filed 2022-02-15 | $254.89M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $63.34M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $132.14M derived: sum of 2 quarters · filed 2022-02-15 | $201.31M derived: sum of 3 quarters · filed 2022-02-15 | $268.57M 10-K · filed 2022-02-15 |
| 2019-09-30 | $68.80M 10-Q · filed 2020-11-12 | $137.96M derived: sum of 2 quarters · filed 2020-11-12 | $205.23M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $69.17M 10-Q · filed 2020-08-12 | $136.43M 10-Q · filed 2020-08-12 | ||
| 2018-12-31 | $279.96M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |